Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cellus Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. Such a focused portfolio suggests a highly specific technical application within the broader biotechnology field, requiring precise navigation of the assigned art unit's standards. The concentration of the portfolio in 1 art unit implies that the company's current intellectual property efforts are localized within a single specialized group at the USPTO.
OTTON, ALICIA L serves as the busiest examiner for the portfolio. This examiner is responsible for 1 pending office action. For a practitioner, this means the entirety of the company's current pending prosecution rests with a single individual, making the examiner's specific tendencies and the art unit's internal guidelines critical to the outcome. The presence of only 1 distinct examiner for the 1 pending action indicates a lack of diversification in current USPTO interactions. This examiner-specific focus requires a strategy tailored to the individual habits of OTTON, ALICIA L within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 64.9% | +9.4% |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865258 | NOVEL CDK7 INHIBITORY COMPOUND, AND USE THEREOF | OTTON, ALICIA L | 1699 | §112 | Non-Final OA | — | Pending | Nov 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial